NCT05251012 is a clinical trial in Coronary Stenosis, sponsored by Pablo Manuel Fernandez Corredoira.

Who is sponsoring NCT05251012?

NCT05251012 is sponsored by Pablo Manuel Fernandez Corredoira.

What condition does NCT05251012 study?

NCT05251012 studies Coronary Stenosis, Coronary Artery Disease.

Is NCT05251012 still recruiting?

NCT05251012 is currently completed. Last updated 22 February 2022.

Last reviewed 2022-02-22 · How we verify

NCT05251012

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3D-QFR in Non-selected Angiographic Stenosis. A Spanish Multicentre Study.

Completed Last updated 22 February 2022

What this trial tests

trial in Coronary Stenosis in 803 participants. Completed in 31 December 2019.

Timeline

1 January 2015

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Pablo Manuel Fernandez Corredoira
Status	Completed
Study type	OBSERVATIONAL
Enrollment	803
Start date	1 January 2015
Primary completion	31 December 2019
Estimated completion	31 December 2019

Conditions studied

Coronary Stenosis — all drugs for Coronary Stenosis →
Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Pablo Manuel Fernandez Corredoira

Who can join

Adults 18 to 90, any sex, with Coronary Stenosis or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Physiology-based decision-making about the need for revascularisation in patients with stable coronary heart disease has consistently proven better clinical outcomes than a merely anatomical approach. However, against the current recommendations, revascularisation in most of patients with chronic coronary syndromes still relies on coronary angiography alone. The increase in costs and in procedural complexity of wire-based physiology may explain the latter. Therefore, a novel non-invasive functional quantitative flow ratio (QFR) index was created in order to solve it. A retrospective and multicentre study is performed to assess the 5-year prognosis of patients undergoing coronary angiography through a centralized QFR analysis. Consecutive participants with confirmed or suspected diagnosis of stable coronary disease who underwent a coronary angiography between 01/01/2015 and 12/31/2015 were included. Aims of the study: * To evaluate the prognosis of stable coronary disease depending on the functional assessment of coronary artery disease. * To determine the % of percutaneous coronary interventions that could be avoided if this study had been carried out through functional assessment of coronary artery disease based on 3-dimensional vessel reconstruction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Agreement between Murray law-based quantitative flow ratio (μQFR) and three-dimensional quantitative flow ratio (3D-QFR) in non-selected angiographic stenosis: A multicenter study.
Cortés C, Liu L, Berdin SL, Fernández-Corredoira PM, et al · · 2022 · cited 26× · PMID 35578755 · DOI 10.5603/cj.a2022.0030

Verify or expand the search:

Other recruiting trials for Coronary Stenosis

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
NCT05709652 — Impact of Fast-rotation Coronary CT in Patients Undergoing Aortic Stenosis Workup · NA · recruiting
NCT06376630 — Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI · NA · recruiting
NCT04014140 — iFR Guided Coronary Artery Bypass Grafting Surgery · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05251012 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pablo Manuel Fernandez Corredoira
Last refreshed: 22 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05251012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing